{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2025:ICDIMADEQZQPGF6Z5QIZPHBE72","short_pith_number":"pith:ICDIMADE","schema_version":"1.0","canonical_sha256":"40868600648660f317d9ec11979c24fe9aa169792521aab71d2ed746edccc816","source":{"kind":"arxiv","id":"2501.04869","version":1},"attestation_state":"computed","paper":{"title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.GN","authors_text":"Alexey Sergushichev, Anna Esteve, Barbara Schmalfeldt, Jan Baumbach, Karen Legler, Kathrin Eylmann, Leticia Oliveira-Ferrer, Malik Alawi, Minyue Qi, Olga Tsoy, Olga Zolotareva, Stefan Kommoss, Vladimir Sukhov","submitted_at":"2025-01-08T22:40:58Z","abstract_excerpt":"The standard of care for ovarian cancer comprises cytoreductive surgery, followed by adjuvant platinum-based chemotherapy plus taxane therapy and maintenance therapy with the antiangiogenic compound bevacizumab and/or a PARP inhibitor. Nevertheless, there is currently no clear clinical indication for the use of bevacizumab, highlighting the urgent need for biomarkers to assess the response to bevacizumab. In the present study, based on a novel RNA-seq dataset (n=181) and a previously published microarray-based dataset (n=377), we have identified an expression signature potentially associated w"},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"2501.04869","kind":"arxiv","version":1},"metadata":{"license":"http://creativecommons.org/licenses/by/4.0/","primary_cat":"q-bio.GN","submitted_at":"2025-01-08T22:40:58Z","cross_cats_sorted":[],"title_canon_sha256":"623b35e764a93ddc67b577f13009a3f7f25db33757c74ce7a7572a2b8b089314","abstract_canon_sha256":"6756fcb11e4decdbbcae535d63f7389755623ff491fe6fcf8cf6170f2bb2e02d"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T09:58:47.812796Z","signature_b64":"IpITDLMaoPNqdWBj7pqAsSS/hWRLDT9ho6hzk8fcWHDHBBYc18qFX0x1XASqABcEQjB5zNu9A0T1cvvcb4cbBw==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"40868600648660f317d9ec11979c24fe9aa169792521aab71d2ed746edccc816","last_reissued_at":"2026-07-05T09:58:47.812359Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T09:58:47.812359Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"Transcriptome signature for the identification of bevacizumab responders in ovarian cancer","license":"http://creativecommons.org/licenses/by/4.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.GN","authors_text":"Alexey Sergushichev, Anna Esteve, Barbara Schmalfeldt, Jan Baumbach, Karen Legler, Kathrin Eylmann, Leticia Oliveira-Ferrer, Malik Alawi, Minyue Qi, Olga Tsoy, Olga Zolotareva, Stefan Kommoss, Vladimir Sukhov","submitted_at":"2025-01-08T22:40:58Z","abstract_excerpt":"The standard of care for ovarian cancer comprises cytoreductive surgery, followed by adjuvant platinum-based chemotherapy plus taxane therapy and maintenance therapy with the antiangiogenic compound bevacizumab and/or a PARP inhibitor. Nevertheless, there is currently no clear clinical indication for the use of bevacizumab, highlighting the urgent need for biomarkers to assess the response to bevacizumab. In the present study, based on a novel RNA-seq dataset (n=181) and a previously published microarray-based dataset (n=377), we have identified an expression signature potentially associated w"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2501.04869","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2501.04869/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"2501.04869","created_at":"2026-07-05T09:58:47.812419+00:00"},{"alias_kind":"arxiv_version","alias_value":"2501.04869v1","created_at":"2026-07-05T09:58:47.812419+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2501.04869","created_at":"2026-07-05T09:58:47.812419+00:00"},{"alias_kind":"pith_short_12","alias_value":"ICDIMADEQZQP","created_at":"2026-07-05T09:58:47.812419+00:00"},{"alias_kind":"pith_short_16","alias_value":"ICDIMADEQZQPGF6Z","created_at":"2026-07-05T09:58:47.812419+00:00"},{"alias_kind":"pith_short_8","alias_value":"ICDIMADE","created_at":"2026-07-05T09:58:47.812419+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72","json":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72.json","graph_json":"https://pith.science/api/pith-number/ICDIMADEQZQPGF6Z5QIZPHBE72/graph.json","events_json":"https://pith.science/api/pith-number/ICDIMADEQZQPGF6Z5QIZPHBE72/events.json","paper":"https://pith.science/paper/ICDIMADE"},"agent_actions":{"view_html":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72","download_json":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72.json","view_paper":"https://pith.science/paper/ICDIMADE","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=2501.04869&json=true","fetch_graph":"https://pith.science/api/pith-number/ICDIMADEQZQPGF6Z5QIZPHBE72/graph.json","fetch_events":"https://pith.science/api/pith-number/ICDIMADEQZQPGF6Z5QIZPHBE72/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72/action/timestamp_anchor","attest_storage":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72/action/storage_attestation","attest_author":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72/action/author_attestation","sign_citation":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72/action/citation_signature","submit_replication":"https://pith.science/pith/ICDIMADEQZQPGF6Z5QIZPHBE72/action/replication_record"}},"created_at":"2026-07-05T09:58:47.812419+00:00","updated_at":"2026-07-05T09:58:47.812419+00:00"}